Anika Therapeutics (STU:AKP) E10: €-0.42 (As of Mar. 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
66 GF Score
Price €13.30
GF Value €18.03
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics E10?

Anika Therapeutics STU:AKP +4.72% 66 E10 is €-0.42 as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 66/100 and a GF Value™ of €18.03 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Anika Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.320. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.42 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Anika Therapeutics was 38.90% per year. The lowest was -22.30% per year. And the median was 16.00% per year.

As of today (2026-07-02), Anika Therapeutics's current stock price is €13.30. Anika Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-0.42. Anika Therapeutics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Anika Therapeutics was 133.58. The lowest was 13.96. And the median was 27.34.


Anika Therapeutics  (STU:AKP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Anika Therapeutics was 133.58. The lowest was 13.96. And the median was 27.34.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Anika Therapeutics E10 Related Terms


Anika Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics E10 Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.26 0.60 -0.03 -0.31

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.16 -0.24 -0.31 -0.42

STU:AKP vs LFCR, DERM, ASRT: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Shiller PE Ratio falls into.


STU:AKP
66GF Score
Anika Therapeutics Inc STU:AKP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.32/330.2130*330.2130
=-0.320

Current CPI (Mar. 2026) = 330.2130.

Anika Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 0.507 241.018 0.695
201609 0.526 241.428 0.719
201612 0.512 241.432 0.700
201703 0.346 243.801 0.469
201706 0.676 244.955 0.911
201709 0.386 246.819 0.516
201712 0.448 246.524 0.600
201803 -0.373 249.554 -0.494
201806 0.582 251.989 0.763
201809 0.454 252.439 0.594
201812 0.475 251.233 0.624
201903 0.274 254.202 0.356
201906 0.593 256.143 0.764
201909 0.581 256.759 0.747
201912 0.252 256.974 0.324
202003 0.362 258.115 0.463
202006 -0.480 257.797 -0.615
202009 -0.382 260.280 -0.485
202012 -0.904 260.474 -1.146
202103 0.168 264.877 0.209
202106 0.374 271.696 0.455
202109 0.034 274.310 0.041
202112 -0.354 278.802 -0.419
202203 -0.182 287.504 -0.209
202206 -0.189 296.311 -0.211
202209 -0.293 296.808 -0.326
202212 -0.321 296.797 -0.357
202303 -0.663 301.836 -0.725
202306 -0.175 305.109 -0.189
202309 -0.422 307.789 -0.453
202312 -3.943 306.746 -4.245
202403 -0.285 312.332 -0.301
202406 -0.009 314.175 -0.009
202409 -1.829 315.301 -1.916
202412 -1.433 315.605 -1.499
202503 -0.314 319.799 -0.324
202506 -0.243 322.561 -0.249
202509 -0.136 324.800 -0.138
202512 0.017 324.054 0.017
202603 -0.320 330.213 -0.320

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.42 mean?
Anika Therapeutics (STU:AKP) has a E10 of €-0.42 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' E10 too high?
Anika Therapeutics' current E10 is €-0.42. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' E10 compare to LFCR and DERM?
Anika Therapeutics' E10 of €-0.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current E10 is €-0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €18.03, compared to a current price of €13.30 — trading 26.2% below its estimated fair value. The current E10 is €-0.42. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current E10 is €-0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.30 is trading 26.2% below its estimated GF Value™ of €18.03. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • E10: €-0.42
  • GF Value™: €18.03 vs. price of €13.30 (26.2% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score

Get the complete analysis for STU:AKP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.30
Price
€18.03
GF Value